---
document_datetime: 2023-09-21 20:52:12
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/ytracis-epar-procedural-steps-taken-authorisation_en.pdf
document_name: ytracis-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.3894272
conversion_datetime: 2025-12-22 11:08:49.145626
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The applicant  submitted on  an application for Marketing Authorisation to the European Agency for the Evaluation of Medicinal Products (EMEA) for Ytracis, through the centralised procedure. After agreement by the CPMP on 23 March 2002 , this medicinal product has been referred to Part B of the Annex to Council Regulation No (EEC) 2309/93 of 22 July 1993 as amended.

The Rapporteur and Co-Rapporteur appointed by the CPMP were:

<!-- image -->

Rapporteur: Dr B. van Zwieten-Boot Co-Rapporteur: Dr J. Ersbøll Licensing status: The product was not licensed in any country at the time of submission of the application. 2. Steps taken for the assessment of the product · The procedure started on 22 October 2001. · The Rapporteur's first Assessment Report was circulated to all CPMP members on 16 January 2002. The Co-Rapporteur's first Assessment Report was circulated on 10 January 2002 to all CPMP members. · During the meeting on 19-21 February the CPMP agreed on the consolidated List of Questions to be sent to the applicant. The final consolidated List of Questions was sent to the applicant on 21 February 2002. · The company submitted the responses to the CPMP consolidated List of Questions on 5 July 2002. · The Rapporteur and Co-Rapporteur circulated their Joint Assessment Report on the company's responses to the List of Questions on 27 August 2002 to all CPMP members. · During the meeting on 17-19 September the CPMP agreed on the List of Outstanding issues to be sent to the applicant. The final List of Outstanding issues was sent to the applicant on 19 September 2002. · The company submitted the responses to the CPMP List of outstanding issues on 17 October 2002. · During  the  meeting  on  19-21  November  2002  the  CPMP,  in  the  light  of  the  overall  data submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for granting a Marketing Authorisation to Ytracis on 21 November 2002. Medicinal product no longer authorised